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Abstract
This project proposed that given a basic model of the decisional logic driving stable
adherence it might be possible to reliably anticipate increased vulnerability to discontinuation
and use such a mode to design behavioral interventions that are specifically tailored to deliver
course corrections that are temporally and contextually optimal. A logistic regression was coded
and run using the core model predicted by the experts as a base for how the variables interact to
make predictions. Then a logistic regression with stepwise selection was coded and run using the
core model as a base for how the variables interact and to allow for variables to be added to
make the prediction more accurate. The logistic regression with stepwise selection produced both
an augmented core model and a de novo model. There were two nodes that had a variable added
over 75% of the time to the augmented core. These nodes were health literacy and treatment
fatigue. The accuracy for the core model, augmented core model, and de novo model were all
accurate with respective overall accuracies being 63.5%, 66.3%, and 67.4%. However, it is
important to note that we were able to outperform the expert model by doing the logistic
regression with stepwise selection. The results show that the causal interaction diagram predicted
by the experts was fairly accurate. These results then can be used to further the research needed
to make a program that will help predict the chances of adherence and to be able help doctors
work with the patients to stay adherent.
Introduction
Breast cancer is the most common type of cancer in women, there are about 1,200,000
new cases of breast cancer each year worldwide.[Lumachi et al., 2013] Though there are several
different subtypes of breast cancer [Russnes et al., 2017] distinguished by histological and

molecular profiles. The current project focuses on estrogen receptor positive (ER+) breast
cancer, a molecular subclass capturing over 70% of breast cancers.
Adjuvant endocrine therapy for stage I-III estrogen receptor positive (ER+) breast cancer
provides a substantial survival benefit[EBCTCG, 2011]. Evidence suggests that despite the
benefits of adherence to adjuvant hormonal treatment (ET) for the full duration, in the first year
discontinuation of adjuvant ET is between 7% to 14% and that may increase to between 31% to
60% by the end of the fifth year. [Winer 2005, Moore, Hadji 2010, Ma 2008] Some of the
benefits of sustained adherence to ET include an increase in the overall chance of survival and
reduced cancer specific mortality, decreased risk of recurrence, and decreased risk of
contralateral breast cancer, which is finding a tumor in the opposite breast of the first
cancer.[Burstein 2014] There are also a number of risks associated with ET as well as significant
deterrents to continued adherence. Though relatively rare, such risks vary from one therapeutic
agent to another and can include developing endometrial cancer, menopausal symptoms, deep
vein thrombosis, pulmonary embolism, ischemic heart disease, osteopenia/osteoporosis, and
uterine cancer.[Chay et al., 2016] Other significant drivers of discontinuation of ET are the
significant side effects which include hot flushes, muscle and joint pain, weight gain, fatigue,
depression, difficulty concentrating, numbness or tingling in the extremities, vaginal dryness,
and hair loss.[Paranjpe et al., 2019]. More recently, Shinn et al. [2019],reported on changes in
the patterns of concerns over the first 5 years of ET in 216 individuals and found that leading
concerns or behaviors driving discontinuation such as forgetfulness, cognitive fatigue, and worry
over treatment cost evolved over time. The results that Shinn et al. found bring up important
questions of how would you intervene early in treatment and late in treatment. Also, what
variables would change based on at what point of treatment the patient is.

There are many different therapies that require adherence to a specific treatment regimen
whether it is a medication or specific exercises. Simpson et al. [2006] studied the connection
between adherence to drug therapy and mortality. They found that good adherence for patients
that were adhering to either placebo or beneficial drug therapy had half the risk of mortality than
those with poor adherence. However if the drug proved harmful, the patients with good
adherence had a higher mortality rate than those with poor adherence. [Simpson et al., 2006].
Narayanan et al. [2017] studied adherence to cystic fibrosis therapies and the effects of not
adhering to treatment. The authors found that for most patients the adherence was subpar, but
this did vary according to the treatment, age of the patient, and even the season. They found that
when patients are adherent to cystic fibrosis therapies, they can experience a lower disease
burden and improve the patient outcomes. However, in patients who did not have good
adherence it was seen that there was a clinical and economic burden of the disease because they
had to receive more treatment later on as a result of not being adherent to their treatment.
Another study of the adherence of oral anticoagulation therapy found that for one treatment there
was an adherence level of 40% and for the other treatment there was an adherence of 47% [Chen
et al., 2020]. Oates et al. [2019] studied the objective versus self-reported adherence rates in
airway clearance therapy in cystic fibrosis. They found that while there was a mean adherence of
61% in the objective findings, the amount of highly adherent subjects was 31% and 28% were
low adherent. The self-reported adherence levels showed 65% of subjects reported themselves as
high adherence and only 8% of them reported low adherence. [Oates et al., 2019] This
overestimated actual adherence could affect other treatments not just cystic fibrosis.
The study done by Chen et al. [2020] found that there were many variables that interacted
with the patient’s decision to discontinue use of the medication or have varying levels of

adherence. Ghembaza et al. [2014] asked if the patient’s knowledge of hypertension
complications on adherence to therapy impacted the patient’s adherence to treatment. While this
is not the same disease that my project is studying, there could be reasons for staying adherent or
becoming non adherent that are not specific to one disease. Ghembaza et al. [2014] found that
there is a positive relationship between what is known about hypertension complications and
adherence to treatment. [Ghembaza et al., 2014]. There have also been studies into predicting if a
patient will stay adherent to therapy. Essery et al. [2016] found a number of factors that
influenced the patient’s adherence to home-based physical therapies. Those factors include
intention to engage in the therapy, self-motivation, self-efficacy, previous adherence to exerciserelated behaviors, and social support.[Essery et al., 2016]. Some of these factors could probably
be applied to other therapies and social support is one that is important in most therapies
including this project.
To increase adherence, the researchers must first find out why the patients are not
adhering to treatment. The consequences for not adhering to the treatment plan can range from
very small to quite large. One disease that has a larger consequence for non-adherence was breast
cancer. It was found in breast cancer patients that those who are non-adherent have a higher
mortality rate. The estimated survival for those who discontinued treatment was 73.6% after 10
years versus 80.7% for those who were adherent to treatment[Hershman et al. 2010]. They found
that the survival at 10 years for those who continued the study had a survival rate of 81.7% if
they were adherent and 77.8% if they were non adherent. This is not a large difference, but it
does prove that those who discontinued early or were non-adherence did have an increased
mortality rate. [Hershman et al., 2011]. Having a predictive program that can account for the
different variables that affect adherence to treatment could be helpful with increasing adherence

to the treatment, thereby improving patient outcome. Being able to predict the next stage that a
variable might be when a person is on a treatment plan can be very helpful to prevent nonadherence. It could be possible that once the program can predict the next stages of the variable
accurately, that it could be developed to accurately predict if a patient will stay adherent to a
medication. This could help doctors prepare for if a patient might become non-adherent and
work with the patient to keep them adherent to the treatment. Keeping a patient adherent to a
treatment could be beneficial to the patient. In patients with cystic fibrosis, adherence to
medication can decrease cost of treatment in the long run and lower disease burden [Narayanan
et al., 2017]. In patients with breast cancer, adherence to treatment leads to an increase in life
expectancy over those who are not adherent[Hershman et al., 2010]. What has been found in all
therapies that have been discussed so far is that staying adherent to any treatment that has been
discussed so far is beneficial to the patient whether it helps them live longer or have reduced
medical bills or just simply have a better quality of life.
Currently, the underlying behavioral processes that govern changes in the relative
importance afforded to these concerns as well as their role in driving an upcoming
discontinuation of therapy are poorly understood. We propose that given a basic model of the
decisional logic driving stable adherence it might be possible to reliably anticipate increased
vulnerability to discontinuation and use such a model to design behavioral interventions that are
specifically tailored to deliver course corrections that are temporally and contextually optimal.
Approaches for extracting such mechanisms or decisional processes from data de novo
include statistical methods based on conditional probabilities such as those initially proposed by
Pearl [2003] however such methods require substantial amounts of numerical data to infer causal
relationships with high confidence. This project does not have a large amount of numerical data

which could make the methods that Pearl discussed more difficult to apply because those
methods are most successful with lots of data. Another approach more suitable to limited data
consists of proposing a set of causal decisional processes, formulating these into a logic network
and comparing the predicted dynamic responses against observed behaviors. This project would
work off of a logical framework similar to what Abou-Jaoude et al. did[2016]. They started with
a logical framework and then defined models and their dynamics where most common variants
are presented focusing on updating schemes and their impacts on dynamical properties. With a
logical framework it is important to take the updating schemes and their impacts on dynamical
properties into account to create an accurate prediction. If the model does not take into account
the dynamics of the model and the data into account when making a prediction the prediction
will not be as accurate as it could be [Abou-Jaoude et al., 2016]. Toole et al. discuss using a logic
model applied to depression that can then be used by a computer program to help make better
predictions or computer simulations[Toole et al., 2018 depression]. Using a preliminary logic
model can give a program a starting point and depending on how accurate the logic model is it
could help the program to make more accurate predictions. Toole et al. used an optimizationbased trial and error to discover novel relationships between well-being and dopamine and
acetylcholine. This allowed for the authors to be able to make a specific feedback network that
would promote well-being by dopamine and acetylcholine levels and promoted norepinephrine
while inhibiting cortisol [Toole et al., 2018 optimization].
Research Question: How would I intervene early in treatment and late in
treatment? What variables would change based on what point of treatment the patient is
at?

The overarching aim of this study was to make a model that predicts the decision to
discontinue treatment based on data from a pilot study. Within that aim, we set out to complete a
decisional network model by comparing the core relationships proposed by a domain expert to
those extracted from the data using a simple logistic regression with stepwise selection based
approach.
Methods
Data.
The data that has been collected on many different variables that may impact the
continuation of therapy, such as cost, side effects, sense of urgency, and others that affect
adherence to adjuvant ET. The data that was collected can be used to look for trends and
determine why people were or were not adhering to the treatment.[GriffinS, 2006]
Events resulting in a change of adherence status were of specific interest. A total of 26
changes in status were observed, namely 5 decisions to resume adherence and 21 decisions to
discontinue. These occur at various phases of ET as outlined in Table 1. Timepoints 9->11 and
11->13 are when most switches to nonadherence occurred. Many more patients became
nonadherent and there were very few that became adherent.

Table 1: Changes in Adherence

Table 1: Adherence changes over time during adjuvant ET. 55/82 subjects entered
adherent and stayed adherent, 4/82 subjects entered non-adherent and stayed nonadherent, 21/82 subjects had at least one change in adherence. There was a total of 26
changes in adherence.
The discretized data needed to be rearranged in a way that the regression would be able to
predict the next time point for the variables from the current time point. For each subject the data
had to be set up so within each subject the timepoints go in pair of two from the first time point
to the next time point, for example time point 1 to 3 then timepoint 3 to 5. The first time point is
listed as the original names of the variable and the second time point has _y added to the end of
the variable names. It is important to note that in Figure 1, there is a node called adherence which
refers to adherence from timepoint x to timepoint y not the overarching adherence to the
medication.

Computational Approach
The data were interrogated through a program that performed probabilistic predictions of
the next state based on data collected at timepoints preceding the current one. The basic
forecasting model was a logistic auto-regressive moving average with exogenous variables or
ARMAX. Both the logistic regression and logistic regression with stepwise selection were set up
to predict the next timepoint based on the previous and current timepoints and the goal was to
accurately predict the state of the variable in the next timepoint.
There were three basic sets of exogenous regressor variables used. First a core model was
proposed by domain experts describing their understanding of cause and effect relationships
driving adherence. The core model details the variable and the variables that are proposed to
have negative or positive causal interactions with that variable. Second, this core model was
augmented with new statistically inferred interactions using a logistic regression with stepwise
selection procedure. This second model starts with the core model and then alternates between
adding and removing new variables until the new variable set is statistically significant in
reducing prediction error. The last model is a de novo logistic regression with stepwise selection
model. The de novo model is created using logistic regression with stepwise selection, but starts
with a blank slate where all of the measured variables are candidates for selection.
The first step to making the logistic regression was to make a multivariate logistic
regression on one of the variables to get used to the program that was being used and to learn
how to have the program allow for multiple variables to interact with the one that was currently
being predicted. Once this was working a multivariate logistic regression was written to run on
each node taking all variables that are predicted to affect the node into account. The training/test

split used for the logistic regression was 30 training, 70 test. The logistic regression was coded in
Python and the sklearn library was used. Using the sklearn library allowed me to use the logistic
regression method that is built into the sklearn library.
The logistic regression algorithm with stepwise selection [Rawlings, 1998] was applied at
each node in turn and new input variables added such that the next state of that node was
predicted with minimal error. The partial F null probability for inclusion of a new term was set to
p = 0.05 for elimination of an existing term. The logistic regression with stepwise selection was
set up in a way that allows for the program to be able to find the highest accuracy for each node.
The logistic regression with stepwise selection was also set up to be able to be run with either the
expert predicted interacts as a starting point for what variables the logistic regression with
stepwise selection should include or with no base suggestions. The logistic regression with
stepwise selection added variables that helped the program make the highest prediction accuracy
for the nodes. The training/test split for the logistic regression with stepwise selection was a 30
training/70 test split like what was done with the logistic regression. The logistic regression with
stepwise selection was programmed in Python and the library sklearn was used for this program
as well. The logistic regression method from sklearn was used to run the logistic regression with
stepwise selection as well because to find the highest prediction a logistic regression was run on
the node and then the logistic regression with stepwise selection part allows for the logistic
regression to continue being run on one variable until the highest prediction is found.

Figure 1: Causal interaction diagram

Figure 1: Causal interaction diagram. This circuit diagram describes the decisional logic
flow across all the variables, how they interact with each other, how they can influence

the overall quality of life and how they influence the patients adherence to the therapy.
(Shinn et al., 2020).
A basic logistic regression was run against the basic structure of the expert-informed core
model to determine its accuracy in reproducing the experimental observations. This was done by
programming a core set of variables for each node according to the connectivity described in
Figure 1. The logistic regression used the measured node state and that of its upstream input
nodes at the current timepoint to predict the node’s state at the next timepoint. The data was
randomly split into two sets, 70% of observations for testing and 30% of observations for
training. These training and test sets were repeatedly subsampled and the logistic regression was
applied 100 times.
Similarly, test and training subset selection and the logistic regression with stepwise
selection were also repeated 100 times in the case of the augmented core model and the de novo
model.
A comparative analysis of the model accuracies produced in each case was performed to
determine if the augmented core model and the de novo models improved prediction accuracy on
average over that obtained by using the expert-informed variant. Null probability p-values were
computed with a threshold for significance of 0.002 to determine if there was a significantly
higher average accuracy from the logistic regression with stepwise selection models compared to
the expert-informed logistic regression results. Likewise, the overall frequency of selection for
each of the candidate input variables was analyzed to identify new upstream modes added to the
core model 75% of the time or more.

All of the calculations for the comparison analysis were performed in Python. The comparison
was done using a t-test as well as the p values and for the t-test the library scipy.stats was used.
Results
Evaluating prediction accuracy an expert-informed model and its variants
Using the basic connectivity at each node as described in Figure 1 and applying a logistic
regression as a state transition function to predict the next state we find that only 3 nodes deliver
an accuracy above 75%. These are the adherence status, treatment cost worry, and patientreported coping deficit. Given the expert-informed model structure the next state of most nodes
is predicted with an accuracy ranging between 50% and 75%, with the exception of numeracy,
and beneficial routine for which prediction accuracy is especially poor (<50%) (Figure 2A). The
addition of novel edges to the core expert model as inferred from the data using a stepwise
selection routine improved the accuracy of most nodes raising the overall average accuracy from
63.53% to 66.34% (p=0.05). The most noticeable increase in average accuracy was observed for
nodes treatment fatigue, adherence, risk perception, cancer worry, health literacy, numeracy,
quality of life, side effects, general anxiety, patient satisfaction with doctor, treatment cost worry,
and beneficial routine. All of these nodes had a p value greater than 0.05. (Figure 2B). Finally,
selecting upstream mediators naively from the data alone, in the absence of any prior structure,
had the effect of normalizing the accuracy across all nodes to an average of roughly 70%.
Average accuracy in the structurally naive model increased for some nodes and decreased for
others but for all nodes the range of accuracy values across the 100 repeated subset selections
increased noticeable from sigma ~ 63.53% to sigma ~ 67.39%. In figure 2C you can see that the
boxes on the graph are much wider than graphs 2A and 2B. This suggests that the accuracy is

dependent on the subset selection and that without a base model to go off of the model is not that
stable.
Figure 2: Predictive accuracy of network variants

Figure 2: Accuracy in predicting the next state for individual nodes using a logistic
regression applied to an expert-informed model structure (A), a stepwise selection of upstream

interactions to be added to the core expert model (B), and a de novo stepwise selection of
upstream from all model nodes (C).
Figure 3: Consensus voting of augmented core model structure

(A)

(B)

Figure 3: Two graphs that show a significant node that had a variable added to it during the
augmented core model run a significant amount of times. The A graph shows the significant
node is treatment fatigue and the variable adherence was added by the regression about 90 times
out of the 100 runs. The B graph shows the significant node is health literacy and the variable
that was added a significant amount of time is anxiety which was about 75% of the time when it
was run.
Figure 4: Consensus voting of de novo model

(A)

(B)

Figure 4: Two of the significant nodes from the de novo model. Graph A represents the
treatment fatigue node and it showed that the adherence variable was added over 90% of the
time. The graph B shows the node for health literacy and the variable anxiety was added to the
prediction about 50% of the time.

Figure 3 focuses on two nodes that had a variable added the majority of times to the
augmented core model out of the 100 runs that were done. Figure 4 focuses on the same two
nodes from Figure 3, but it is looking to see if the variables that were added the majority of the
runs to the augmented core model were also added during to the de novo model. The two nodes
that are looked at in these figures are health literacy and treatment fatigue. In figure 3A you can
see that general anxiety is added the majority of the runs to the node health literacy and in figure
4A general anxiety is added to the health literacy node about 50% of the time which is more than
any other variable for that node. In figure 3B you can see that the variable, adherence, was added

the majority of the time to the node, treatment fatigue and in figure 4B adherence was also added
the majority of the runs to the treatment fatigue node.
Table 2: The average accuracy score for each node.
Nodes

Core Model

Augmented Core

De novo Model

Model
Treatment fatigue

0.5985

0.6448

0.6653

Adherence

0.7671

0.7786

0.8126

Risk Perception

0.5409

0.5751

0.5982

Cancer Worry

0.5666

0.6016

0.6253

Health literacy

0.5890

0.6302

0.6316

Numeracy

0.4095

0.4526

0.4578

Quality of Life

0.7015

0.7160

0.7349

Side Effects

0.5734

0.6140

0.6137

General Anxiety

0.6800

0.7184

0.7187

Patient Satisfaction
with Doctor

0.7010

0.7098

0.7130

Cost Worry

0.8469

0.8603

0.8582

Beneficial Routine

0.4213

0.4575

0.4655

Coping Deficit

0.8635

0.8653

0.8659

Table 2: Average accuracy score of each node. The first column labeled “Core Model” which is
the average accuracy of each node when the data was run through the logistic regression. The
second column “Augmented Core Model” which is the average accuracy of each node when run
through the logistic regression with stepwise selection. The third column “De novo Model” is the
average accuracy of each node when run through the logistic regression with stepwise selection.

Of the 13 nodes re-evaluated by applying stepwise feature selection to augment the
expert core model, 12 showed significantly improved average prediction accuracy with a less
than 0.05 p value. These 12 nodes were treatment fatigue, adherence, risk perception, cancer
worries, health literacy, numeracy, quality of life, side effects, general anxiety, patient
satisfaction with doctor, treatment cost worry, and beneficial routine.
In the de novo model assembled without prior knowledge of structure we also found 11
out of 13 nodes that improved significantly in accuracy compared to the logistic regression
model. The 11 nodes that are significant are treatment fatigue, adherence, risk perception, cancer
worries, health literacy, numeracy, quality of life, side effects, treatment cost worry, beneficial
routine, and coping deficit. In the de novo model there were also 3 nodes that had a 5% or more
increase in accuracy. Those nodes were treatment fatigue, risk perception, and cancer worry.

Figure 5: Updated causal interaction diagram

Figure 5: The two new novel edges were added with gray arrows to the original causal
interaction diagram to make the updated causal interaction diagram. One of the new novel edges

is generalized anxiety’s connection to Health literacy and the other is adherence’s connection to
treatment fatigue. These are the variables that were added the majority of the times during the
logistic regression with stepwise selection.
The two connections that were added in figure 5 were determined based on what was
seen in figure 3 and figure 4. The accuracy for the node treatment fatigue increased quite a bit
during the logistic regression with stepwise selection for both the augmented core model and the
de novo model and the logistic regression with stepwise selection added the variable adherence
when it was predicting the outcome for treatment fatigue. When generalized anxiety was added
to the node health literacy by the logistic regression with stepwise selection to both the
augmented core model and the de novo model, there was an increase in accuracy seen.
Model stability and contribution of prior knowledge
The variability in the de novo model is quite a bit larger than that seen in the core model
and the augmented core model, seen in Figure 2. Variability increased for a few different nodes.
The variability increased for the nodes treatment fatigue, risk perception, health literacy,
numeracy, quality of life, side effects, patient satisfaction with doctor, and cost worry. The
standard deviation for treatment fatigue for the de novo model was 0.0343 while the standard
deviation for the augmented core model was 0.0254. For the node, risk perception, the standard
deviation of the de novo model was 0.266 and the standard deviation of the augmented core
model was 0.255. The standard deviation of health literacy of the de novo model was 0.0288 and
the standard deviation for the augmented model was 0.266. The node numeracy had the standard
deviation of the de novo model was 0.248 and the augmented core model was 0.214. 0.0190 was
the standard deviation of the node quality of life for the de novo model and 0.0186 was the

standard deviation for this node for the augmented core model. The node, side effects, when
looking at the standard deviation from the de novo model it was 0.2655 which is higher than the
standard deviation of the augmented core model was 0.259. The node, patient satisfaction with
doctor, had a standard deviation of 0.0189 in the de novo model and this is an increase from the
standard deviation of 0.0173 in the augmented core model. Coping deficit was the last node that
had an increase in variability from the augmented core model to the de novo model when looking
at the standard deviation. The standard deviation for the de novo model was 0.139 and the
standard deviation for the augmented core model was 0.123. The standard deviations are fairly
similar, but there is more variability seen in many of the nodes in the de novo model than the
variability seen in the augmented core model.
Discussion
The experts that created the putative network model were correct about most nodes and
which variables interact with each node. There were a couple nodes that had variables added
consistently when the logistic regression with stepwise selection was run. One node where that
happened is the treatment fatigue node which had adherence added to it almost every run. The
other node where consistent improvements were made is the health literacy node which had
general anxiety added to it almost every run. Overall the expert opinions were quite accurate and
were a very good starting point when it came to predicting the next timepoint for that node.
When you look at the average of all nodes when running the logistic regression with
stepwise selection for either the de novo or the augmented core model the average is higher than
when the logistic regression is run with the core model. The de novo model had an average node
score of 67.4% and the augmented core model had an average node score of 66.3% which is

compared to the average node score of 63.5% from the logistic regression. There were some
nodes that had a very high accuracy for each method and then there were some that had a
consistently low accuracy for each method. When considering the overall goal of this project it is
important to have as high a possible accuracy for each node. This is because it will help with a
better performance in the final program that could be used in a clinical setting.
Results presented in Figure 2, that both the core model and the augmented core model
produced a relatively consistent accuracy from one subsample of data in predicting the next state
for each individual node. However, we observed a broad disparity in the average prediction
accuracy from one node to the next. The opposite was true of the de novo assembled model
where a much broader range of accuracy values at each node was obtained from one data
subsample to the next while the average performance across nodes was much more uniform.
The augmented core model and the core model nodes in Figure 2 do not have much
variation between the accuracy of each node. For the core model that was expected because the
accuracy would not be expected to change much since the variables stay the same the whole
time. The augmented core model also did not change much because for most of the nodes the
predicted core model from the experts were accurate.
One frequent reason for that can be traced back to changes in the coordinated patterns
exhibited in each of the subsampled data sets. For this project, we are trying to find a universal
model for all subjects, but this type of subset specific results could suggest that it might be more
appropriate to stratify the subjects and have multiple models which could be either one per
subject or data subset. In addition, to make this even more complicated the regressor variables
are not statistically independent - they are more or less coupled as they are all members of a

biological regulatory network and as such their measurements will be expressed in specific
patterns. These patterns may shift significantly from one data subset to another affecting the
choice of model terms at each step. However, when we look at the core model and the
augmented core the accuracy values appear quite consistent and vary over a very narrow range.
This could mean that the data subsets might also be reasonably consistent. This points to the
model structure itself and the degrees of freedom with which new terms can be chosen. Figure 3
and 4 show how in both the augmented core model and the de novo model have a variable added
consistently to a node. The nodes that have a variable added consistently during the runs in both
the augmented core model and the de novo model are the health literacy node and the treatment
fatigue node. There were only two nodes that had a variable added consistently which suggested
a broad range of statistically equivalent solutions [Rawling, 1988]. By setting a priori a number
of initial input variables, the choices available for new terms were limited, which decreases the
degrees of freedom, and produces a more narrow family of models since most of the model is
predetermined. This seems to be a more likely culprit.
The health literacy node had the variable general anxiety added the majority of the runs
for both the augmented core model and the de novo model. The treatment fatigue node had the
variable adherence added to the majority of the runs for the augmented core model as well as the
de novo model. Having these nodes be added more than 75% of the time in the augmented core
model and about 50% of the time in the de novo model means that these variables make it more
likely to cause the prediction to be more accurate. Health literacy had general anxiety added the
majority of the runs and these suggest that node general anxiety interacted with the node health
literacy and when included in the model for that node it led to better predictions for the next
timepoint. The same thing is true for the node treatment fatigue and the augmented core model

added the node adherence the majority of the time. This most likely means that the node
adherence has some interaction with the node treatment fatigue and when it is included in the
model it increases the number of correct predictions for the next timepoint of treatment fatigue.
There are a few limitations that could occur with this project. One of the limitations is
that the sample size of the data is small which means that it could be difficult to use probability
to reliably predict any changes in drug adherence. Though incomplete these models can serve as
a basis for adjusting the recruitment and assessment protocols to focus on higher risk individuals
such that the information content of new data is increased in a specific and premeditated way
[Vashishtha et al., 2015; Vildela et al., 2015] - picking specific variables to focus and to use
studies on similar data to make specific assumptions about what data variables are most
important to focus on. There will have to be a specific type of distribution assigned to the data
and the specific assumptions will be used to determine how to make the Petri nets based off of
studies that have been done on similar types of data. [Rawlings J, 1998]
While there were a few limitations to take into account during this project, the program
was still accurate for many of the nodes. Using a logistic regression with stepwise selection
allowed for the discovery for a couple nodes that benefited from having another variable added.
Other than the couple nodes that benefited from a variable being added, the expert made causal
interaction diagram that was quite accurate and allowed the logistic regression to make accurate
predictions for most variables. One variable that had fairly low accuracy was beneficial routine.
There could be multiple reasons for that, one of which could be that there is not enough
knowledge about what can affect that node and the variable that would affect it is not currently
one of the variables that is part of the model. Another factor to consider is that to increase the
accuracy of some of the nodes there would have to be more timepoints for the node. The current

study used a questionnaire every six months, but some of these variables might have had a higher
accuracy if the questionnaire was every week, but that is not something that can be done in a
clinical setting.
Conclusion
Though the addition of new data-informed relationships did improve the predictive
performance of the state transition function at least somewhat at a majority of nodes the basic
expert-informed model nonetheless performed surprisingly well. Moreover, the inclusion of this
baseline prior knowledge as a core model scaffold served to reign in the high degrees of freedom
and reduce the range of solutions compared to the completely naive de novo approach. This is
especially important in cases where there is little data to provide such constraints and where
highly interrelated variables amplify the number of statistically equivalent models. Further
improvements are needed before accurate predictions of adherence to therapy can be made.
Additional data would further strengthen the validation and the current models could support the
design of information recruitment strategies.
Predicting the next timepoint of each individual node is the first step in creating a
program that is able to accurately predict the chance of adherence to the treatment. Having a
program that is able to accurately predict the chance of adherence from one timepoint to the next
could be useful in a clinical setting. The program could be used in a clinical setting by entering
in the patient’s scores for each variable and then using the program to predict if they will
continue to be adherent to the treatment. Then using the results from the program the patient’s
doctor would be able to discuss with them reasons why they might not continue treatment and
the doctor could try to work with the patient so they continue the ET.

While this project focused specifically on making a model that was able to make
predictions in relation to variables thought to affect ET, this thinking and application of machine
learning could be applied to other treatments for cancer and other diseases as well.
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